469PHighly selective c-Met inhibitor tepotinib plus gefitinib is active in Asian patients with c-Met+ NSCLC

2015 
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    5
    Citations
    NaN
    KQI
    []